Abstract | BACKGROUND/AIM: PATIENTS AND METHODS: We included 70 patients with mCRPC who received enzalutamide sequentially following abiraterone treatment. Decline in the prostatespecific antigen (PSA) levels at 4 weeks after enzalutamide initiation and the association between decline in PSA levels and survival were analyzed. RESULTS: Sixteen men (22.9%) achieved a decline of >50% in PSA levels after 4 weeks of enzalutamide administration. Overall survival (OS) after enzalutamide among men with >50% decline at 4 weeks was significantly better than that among men with a PSA decline <50% (not reached vs. 34 months, p=0.008). OS after first-line abiraterone treatment for men with PSA decline >50% and <50% was not reached and 46 months, respectively (p=0.007). A PSA decline of >50% at 4 weeks of enzalutamide administration was an independent predictor of longer OS. CONCLUSION: A PSA decline of >50% at 4 weeks after the start of sequential enzalutamide treatment following abiraterone treatment predicted long-term survival in patients with mCRPC. Early PSA decline can identify patients who benefit from second-line enzalutamide after abiraterone treatment and can be useful as a decision-making tool regarding treatment.
|
Authors | Naohiro Fujimoto, Akinori Minato, Tsukasa Igawa, Tasuku Hiroshige, Wataru Obara, Atsushi Fukuda, Yujiro Nagata, Yui Mizushima, Ikko Tomisaki, Kenichi Harada |
Journal | Anticancer research
(Anticancer Res)
Vol. 42
Issue 6
Pg. 3041-3047
(Jun 2022)
ISSN: 1791-7530 [Electronic] Greece |
PMID | 35641266
(Publication Type: Journal Article)
|
Copyright | Copyright © 2022 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved. |
Chemical References |
- Androstenes
- Benzamides
- Nitriles
- Taxoids
- Docetaxel
- Phenylthiohydantoin
- enzalutamide
- Prostate-Specific Antigen
- abiraterone
|
Topics |
- Androstenes
- Benzamides
- Docetaxel
(therapeutic use)
- Humans
- Male
- Nitriles
- Orchiectomy
- Phenylthiohydantoin
- Prostate-Specific Antigen
- Prostatic Neoplasms, Castration-Resistant
(drug therapy, pathology)
- Taxoids
(therapeutic use)
- Treatment Outcome
|